Find My Journal

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U. Blank, Wilson H. Miller, Eckhart Kaempgen, Salvador Martín‐Algarra, Bogusława Karaszewska, Cornelia Mauch, Vanna Chiarion‐Sileni, Anne-Marie Martin, S. Swann, Patricia Haney, Beloo Mirakhur, Mary Guckert, Vicki Goodman, Paul B. Chapman

The Lancet, 2012

University of Lübeck, University Hospital Schleswig-Holstein, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Russian Cancer Research Center NN Blokhin, Hôpital Saint-André, Medizinische Hochschule Hannover, University of Western Australia, Sir Charles Gairdner Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, The Netherlands Cancer Institute, Jewish General Hospital, Comprehensive Cancer Center Erlangen, Universitätsklinikum Erlangen, Clinica Universidad de Navarra, University Hospital Cologne, Istituto Oncologico Veneto, GlaxoSmithKline (United States), Memorial Sloan Kettering Cancer Center

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

2955

Citations

View on Google Scholar